RRAM-Neuromorphic Fusion Drives Robotics, Exoskeletons Gains

Open PDF
Stock Dorsavi Ltd (DVL.ASX)
Release Time 21 Apr 2026, 9:11 a.m.
Price Sensitive Yes
 RRAM-Neuromorphic Fusion Drives Robotics, Exoskeletons Gains
Key Points
  • Technical validation confirms dorsaVi's RRAM platform and neuromorphic IP portfolio provide a credible pathway toward ultra-edge intelligence
  • Projected 10x performance gains through memory, signal conversion and compute functions integration
  • Combined platform suited for applications requiring fast local decision-making, low power and on-device adaptation
Full Summary

dorsaVi Limited (ASX: DVL) has completed a technical validation confirming that the Company's proprietary RRAM memory technology and its neuromorphic processing IP work effectively together -- establishing a clear pathway toward intelligent, low-power hardware for robotics, exoskeletons and advanced wearable devices. The validation found the two technologies are extremely well suited to work together, forming a credible, validated foundation for building intelligent hardware that can sense, process and respond locally -- on the device itself -- without sending data to the cloud. This technical synergy represents a powerful value proposition where the fusion of high-durability RRAM and neuromorphic processing creates a proprietary ultra-edge architecture that is difficult and expensive to replicate. The validated architecture has the potential to deliver 10x performance gains across applications such as faster control response, improved power efficiency, adaptive exoskeleton and prosthetic control, and stronger robotics performance in latency-constrained environments. The markets targeted by this platform are large and growing rapidly, with the global exoskeleton market projected to reach US$1.79 billion by 2033 and the broader humanoid robotics market attracting over US$5 billion in investment since 2020.

Outlook

DVL intends to continue validation work across the second group of neuromorphic IP assets -- the sensing and signal interface technologies that sit at the front end of the platform, translating real-world inputs from the body and environment into data the system can act on. This validation is expected to further strengthen the case for the combined platform across exoskeleton, robotics and wearable applications.